Corbus Pharmaceuticals is focused on the development and commercialization of novel therapeutics by harnessing its platform of endocannabinoid system-targeting drug candidates. The company’s lead product candidate, lenabasum, is designed to resolve inflammation, limit fibrosis and support tissue repair. Lenabasum is not approved for the treatment of dermatomyositis.
